Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: A convection-enhanced drug delivery study in rats

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3609-3616

  Goldberg, Liat ^a   Ocherashvilli, Aharon ^b   Daniels, Dianne ^b   Last, David ^b   Cohen, Zvi R ^c   Tamar, Gregory ^b   Kloog, Yoel ^a   Mardor, Yael ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Advanced Technology Center   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; SALIRASIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CATHETER; CELL GROWTH; CELL MIGRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; GLIOSARCOMA; GROWTH RATE; IMAGING; MALE; NEUROTOXICITY; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; RAT; THERMODYNAMICS; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CATHETERS, INDWELLING; DRUG DELIVERY SYSTEMS; FARNESOL; MAGNETIC RESONANCE IMAGING; MALE; RAS PROTEINS; RATS; RATS, INBRED F344; SALICYLIC ACIDS; SIGNAL TRANSDUCTION;

EID: 56249112315     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0488     Document Type: Article

References (37)

1. Rosenberg GA, Kyner WT, Estrada E. Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol 1980;238:F42-9.
2. Reulen HJ, Graham R, Spatz M, Klatzo I. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg 1977;46:24-35.
3. Ohata K, Marmarou A. Clearance of brain edema and macromolecules through the cortical extracellular space. J Neurosurg 1992;77:387-96.
4. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021-9.
5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-80.
6. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 1994;266:R292-305.
7. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100:472-9.
8. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.
9. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65:27-35.
10. Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 2003;65:15-25.
11. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003;65:37-48.
12. Mardor Y, Rahav O, Zauberman Y, et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 2005;65:6858-63.
13. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54.
14. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15 609-15.
15. Joneson T, White MA, Wigler MH, Bar Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 1996;271:810-2.
16. Goldberg L, Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006;66:11709-17.
17. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
18. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993;363:15-6.
19. Haklai R, Gana-Weisz M, Elad G, et al. Dislodgment and accelerated degradation of Ras. Biochemistry 1998;37:1306-14.
20. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death. Cancer Res 2005;65:999-1006.
21. Blum R, Nakdimon I, Goldberg L, et al. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 2006;119:527-38.
22. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 1995;38:126 7-72.
23. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997;14:623-5.
24. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007;6:1765-73.
25. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005;11:4321-30.
26. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006;12:5533-42.
27. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002;8:555-65.
28. Markert J. Glioblastoma multiforme: introduction. Cancer J 2003;9:148.
29. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997;15:2755-65.
30. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat 2005;8:369-80.
31. Weisz OA, Schnaar RL. Hepatocyte adhesion to carbohydrate-derivatized surfaces. II. Regulation of cytoskeletal organization and cell morphology. J Cell Biol 1991;115:495-504.
32. Egozi Y, Weisz B, Gana-Weisz M, Ben-Baruch G, Kloog Y. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 1999;80:911-8.
33. Jansen B, Schlagbauer-Wadl H, Kahr H, et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A 1999;96:14019-24.
34. Weisz B, Giehl K, Gana-Weisz M, et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999;18:2579-88.
35. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, et al. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 1999;77:792-7.
36. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008;61:89-96.
37. Shohami E, Yatsiv I, Alexandrovich A, et al. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model. J Cereb Blood Flow Metab 2003;23:728-38.